Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.

Background: Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable responses to treatment and outcome.

Methods: To assess the roles of serum free light chain (sFLC) and K/L FLC ratio (rFLC) in the diagnoses and prognoses of multiple myeloma (MM), sFLC levels and K/L ratios were measured in 112 patients with newly diagnosed multiple myeloma using the Freelite automated immunoassay.

Results: Abnormal sFLC and/or rFLC levels were detected 99.